Project Grant R44HD118842
Award Date 9/17/25
Completion Date 8/31/26
Dollars Obligated $347K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dorchester, MA 02125, USA
Similar Awards
- This $324,984 Project Grant was awarded on August 1, 2025 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Syntis Bio Inc., is developing an innovative oral therapy for treating homocystinuria, a rare metabolic disorder. The project involves optimizing a formulation that combines a protease-stable enzyme (methionine-gamma-lyase) with a...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $343,635 to Syntis Bio Inc. to advance the development of SYNT-213, a potentially transformative once-daily oral therapy for the treatment of Maple Syrup Urine Disease (MSUD). The project aims to optimize SYNT-213, which combines Syntis Bio's Gastrointestinal Synthetic Epithelial Lining (GSEL) technology with a protease-stable leucine decarboxylase enzyme...
- This Project Grant award of $230,250 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research on reversing disrupted developmental sterol biosynthesis caused by prescription medications. The research aims to find a treatment for Smith-Lemli-Opitz Syndrome (SLOS), a rare genetic disorder that disrupts cholesterol biosynthesis, by reducing toxic 7-DHC levels and counteracting...
- This $449,636 Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop a novel SIRNA-based treatment approach to enhance G-Protein Signaling Alpha (Gsa)-mediated hormone signaling. The grant supports research to target the silencing mechanism of the paternal Gsa allele in order to restore hormone responsiveness in patients with...
- This $288,000 Project Grant was awarded on August 4, 2025 by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research federal grant program (CFDA 93.865). The grant supports research conducted by the Van Andel Research Institute in Grand Rapids, Michigan to investigate fatty acid metabolism and identify potential therapeutic targets for treating mitochondrial fatty acid synthesis (MTFAS)...
- This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $722,587 to Neurogt Inc., a biotechnology company in North Carolina, to further develop an effective gene replacement therapy product for treating Mucopolysaccharidosis (MPS) I. The goal of this Phase II Small Business Innovation Research (SBIR) project is to advance a novel self-complementary adeno-associated virus (scAAV) gene therapy vector,...
- This $803,958 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports the development of an innovative approach to deliver a more biologically stable form of the enzyme acid β-glucosidase (GCase) through the blood-brain barrier into the central nervous system. The goal is to enable treatment for neuronopathic Gaucher disease, a...
- This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to establish proof-of-concept for applying targeted fluorination to enhance the pharmacological properties of recombinant protein therapeutics (RPTs) for the treatment of inborn errors of metabolism. The $306,873 award to Halide Biologics, Inc. will fund the development of novel RPT variants with...
- This federal Project Grant award, valued at $534,899.00 and running from June 1, 2025 to February 28, 2030, is funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award aims to define the syndrome of combined methylmalonic acidemia and homocystinuria, cblC-type (CBLC) - an inborn error of cobalamin (vitamin B12) metabolism - as a neurocristopathy impacting...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...